CAR T cell immunotherapy for human cancer

Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia

Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849

Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia

Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509

Cancer regression in patients after transfer of genetically engineered lymphocytes

Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

Morgan, R. A., Yang, J. C.-H., Kitano, M., Dudley, M. E., Laurençot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,564

Adoptive cell transfer as personalized immunotherapy for human cancer

Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,545

T cell exclusion, immune privilege, and the tumor microenvironment

Joyce, J. A., & Fearon, D. T. (2015) · Science · doi:10.1126/science.aaa6204 · Cited by 2,539

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

Kalos, M. D., Levine, B. L., Porter, D. L., Katz, S. I., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,417

Hypoxia-inducible factor activity promotes antitumor effector function and tissue residency by CD8+ T cells

Liikanen, I., Lauhan, C. R., Quon, S., Omilusik, K. D., Phan, A. T., Bartrolí, L. B., Ferry, A., Goulding, J., Chen, J., Scott-Browne, J. P., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143729 · Cited by 160

Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects

Liu, Z., Liu, X., Liang, J., Liu, Y., Hou, X., Zhang, M., Li, Y., & Jiang, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.765101 · Cited by 151

Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors

Chen, T. R., Wang, M., Chen, Y., & Liu, Y. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03315-3 · Cited by 170

Chimeric antigen receptor T cell therapy for autoimmune disease

Chung, J. B., Brudno, J. N., Borie, D. C., & Kochenderfer, J. N. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01035-3 · Cited by 159

Unlocking the full potential of memory T cells in adoptive T cell therapy for hematologic malignancies

Sun, D.-Y., Hu, Y.-J., Li, X., Peng, J., Dai, Z., & Wang, S. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113392 · Cited by 162

Biological Products: Cellular Therapy and FDA Approved Products

Golchin, A., & Farahany, T. Z. (2019) · Stem Cell Reviews and Reports · doi:10.1007/s12015-018-9866-1 · Cited by 148

Why and where an HIV cure is needed and how it might be achieved

Ndung’u, T., McCune, J. M., & Deeks, S. G. (2019) · Nature · doi:10.1038/s41586-019-1841-8 · Cited by 153

A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies

Skokos, D., Waite, J. C., Haber, L., Crawford, A., Hermann, A., Ullman, E., Slim, R. M., Godin, S., Ajithdoss, D. K., Ye, X., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw7888 · Cited by 151

Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons

Zhao, Q., Jiang, Y., Xiang, S., Kaboli, P. J., Shen, J., Zhao, Y., Wu, X., Du, F., Li, M., Cho, C. H., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.658753 · Cited by 150

Metabolic challenges and interventions in CAR T cell therapy

Peng, J.-J., Wang, L., Li, Z., Ku, C., & Ho, P. (2023) · Science Immunology · doi:10.1126/sciimmunol.abq3016 · Cited by 156

Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions

Alnefaie, A., Albogami, S. M., Asiri, Y. A., Ahmad, T., Alotaibi, S. S., Al-Sanea, M. M., & Althobaiti, H. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.797440 · Cited by 163

Co-localized delivery of nanomedicine and nanovaccine augments the postoperative cancer immunotherapy by amplifying T-cell responses

Liu, X., Feng, Z., Wang, C., Su, Q., Song, H., Zhang, C., Huang, P., Liang, X., Dong, A., Kong, D., et al. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119649 · Cited by 148

Fine-Tuning Cytokine Signals

Lin, J., & Leonard, W. J. (2019) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042718-041447 · Cited by 150

Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives

Qu, J., Mei, Q., Chen, L., & Zhou, J. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02735-0 · Cited by 150

Polysaccharide-based nanomedicines for cancer immunotherapy: A review

Zeng, Y., Xiang, Y., Sheng, R., Tomás, H., Rodrigues, J., Gu, Z., Zhang, H., Gong, Q., & Luo, K. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.03.008 · Cited by 150

CAR T Cell-Based Immunotherapy for the Treatment of Glioblastoma

Maggs, L., Cattaneo, G., Dal, A. E., Moghaddam, A. S., & Ferrone, S. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.662064 · Cited by 148

3D-organoid culture supports differentiation of human CAR+ iPSCs into highly functional CAR T cells

Wang, Z., McWilliams‐Koeppen, H. P., Reza, H., Ostberg, J. R., Chen, W., Wang, X., Huynh, C., Vyas, V., Chang, W.-C., Starr, R., et al. (2022) · Cell stem cell · doi:10.1016/j.stem.2022.02.009 · Cited by 148

Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8+ T Cells

Etxeberría, I., Bolaños, E., Quetglas, J. I., Gros, A., Villanueva, A., Palomero, J., Sánchez-Paulete, A. R., Piulats, J. M., Matías‐Guiu, X., Olivera, I., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.10.006 · Cited by 146

The use of RNA-based treatments in the field of cancer immunotherapy

Chehelgerdi, M., & Chehelgerdi, M. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01807-w · Cited by 149

Immune regulation of metastasis: mechanistic insights and therapeutic opportunities

Blomberg, O. S., Spagnuolo, L., & de Visser, K. E. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.036236 · Cited by 145

Chimeric antigen receptor costimulation domains modulate human regulatory T cell function

Boroughs, A. C., Larson, R. C., Choi, B. D., Bouffard, A. A., Riley, L. S., Schiferle, E. B., Kulkarni, A. S., Cetrulo, C. L., Ting, D. T., Blazar, B. R., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.126194 · Cited by 140

Evaluating natural killer cell cytotoxicity against solid tumors using a microfluidic model

Ayuso, J. M., Truttschel, R., Gong, M. M., Humayun, M., Virumbrales-Munoz, M., Vitek, R., Felder, M., Gillies, S. D., Sondel, P., Wisinski, K. B., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2018.1553477 · Cited by 142

Exploration of the relationships between tumor mutation burden with immune infiltrates in clear cell renal cell carcinoma

Zhang, C., Li, Z., Qi, F., Hu, X., & Luo, J. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.10.84 · Cited by 143

Dissecting the biology of allogeneic HSCT to enhance the GvT effect whilst minimizing GvHD

Blazar, B. R., Hill, G. R., & Murphy, W. J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0356-4 · Cited by 148

New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis

Etxeberría, I., Glez‐Vaz, J., Teijeira, Á., & Melero, I. (2019) · ESMO Open · doi:10.1136/esmoopen-2020-000733 · Cited by 149

Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade

Pai, C.-C. S., Huang, J. T., Lu, X., Simons, D. M., Park, C., Chang, A., Tamaki, W., Liu, E., Roybal, K. T., Seagal, J., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.01.006 · Cited by 141

Next-generation cell therapies: the emerging role of CAR-NK cells

Başar, R., Daher, M., & Rezvani, K. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002547 · Cited by 145

Engineering advanced logic and distributed computing in human CAR immune cells

Cho, J. H., Okuma, A., Sofjan, K., Lee, S., Collins, J. J., & Wong, W. W. (2021) · Nature Communications · doi:10.1038/s41467-021-21078-7 · Cited by 143

In vivo CAR engineering for immunotherapy

Li, Y.-R., Zhu, Y., Halladay, T., & Yang, L. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01174-1 · Cited by 151

CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells

Alcantara, M., Tesio, M., June, C. H., & Houot, R. (2018) · Leukemia · doi:10.1038/s41375-018-0285-8 · Cited by 142

Immunotherapy for hepatocellular carcinoma: Current status and future perspectives

Mandlik, D. S., Mandlik, S. K., & Choudhary, H. B. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i6.1054 · Cited by 144

Deletion of Cbl-b inhibits CD8 + T-cell exhaustion and promotes CAR T-cell function

Kumar, J., Kumar, R., Singh, A. K., Tsakem, E. L., Kathania, M., Riese, M. J., Theiss, A. L., Davila, M. L., & Venuprasad, K. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001688 · Cited by 139

Immunogenomics Analysis Reveals that TP53 Mutations Inhibit Tumor Immunity in Gastric Cancer

Jiang, Z., Liu, Z., Li, M., Chen, C., & Wang, X. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.07.012 · Cited by 136

Cytokine release syndrome: grading, modeling, and new therapy

Liu, D., & Zhao, J. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0653-x · Cited by 141

Nanobody Engineering: Toward Next Generation Immunotherapies and Immunoimaging of Cancer

Chanier, T., & Chames, P. (2019) · Antibodies · doi:10.3390/antib8010013 · Cited by 140

Supercharging adoptive T cell therapy to overcome solid tumor–induced immunosuppression

Mardiana, S., Solomon, B., Darcy, P. K., & Beavis, P. A. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw2293 · Cited by 140

Beyond the EPR effect: Intravital microscopy analysis of nanoparticle drug delivery to tumors

Belyaev, I. B., Griaznova, O. Y., Yaremenko, A. V., Deyev, S. M., & Zelepukin, I. V. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115550 · Cited by 145

Cancer: An unknown territory; rethinking before going ahead

Upadhyay, A. (2020) · Genes & Diseases · doi:10.1016/j.gendis.2020.09.002 · Cited by 164

Cell‐Based Delivery Systems: Emerging Carriers for Immunotherapy

Li, Z., Wang, Y., Ding, Y., Repp, L., Kwon, G. S., & Hu, Q. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202100088 · Cited by 138

Scattered seeding of CAR T cells in solid tumors augments anticancer efficacy

Li, H., Wang, Z., Ogunnaike, E. A., Wu, Q., Chen, G., Hu, Q., Ci, T., Chen, Z., Wang, J., Wen, D., et al. (2021) · National Science Review · doi:10.1093/nsr/nwab172 · Cited by 137

Targeting Tumor Glycans for Cancer Therapy: Successes, Limitations, and Perspectives

Berois, N., Pittini, Á., & Osinaga, E. (2022) · Cancers · doi:10.3390/cancers14030645 · Cited by 145

Next-Generation Cancer Immunotherapy Targeting Glypican-3

Shimizu, Y., Suzuki, T., Yoshikawa, T., Endo, I., & Nakatsura, T. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00248 · Cited by 139

Nanotechnology approaches in the current therapy of skin cancer

Borgheti-Cardoso, L. N., Viegas, J. S. R., Silvestrini, A. V. P., Caron, A. L., Praça, F. S. G., Kravicz, M., & Bentley, M. V. L. B. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.02.005 · Cited by 141

Symphony of nanomaterials and immunotherapy based on the cancer–immunity cycle

Li, Q., Shi, Z., Zhang, F., Zeng, W., Zhu, D., & Mei, L. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.05.031 · Cited by 136

A covalent inhibitor of K-Ras(G12C) induces MHC class I presentation of haptenated peptide neoepitopes targetable by immunotherapy

Zhang, Z., Rohweder, P. J., Ongpipattanakul, C., Basu, K., Bohn, M.-F., Dugan, E. J., Steri, V., Hann, B., Shokat, K. M., & Craik, C. S. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.07.005 · Cited by 136

Tim-3 expression and its role in hepatocellular carcinoma

Liu, F., Liu, Y., & Chen, Z. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0667-4 · Cited by 138

The NK-92 cell line—30 years later: its impact on natural killer cell research and treatment of cancer

Klingemann, H. (2023) · Cytotherapy · doi:10.1016/j.jcyt.2022.12.003 · Cited by 135

Next-generation manufacturing protocols enriching TSCM CAR T cells can overcome disease-specific T cell defects in cancer patients

Arcangeli, S., Falcone, L., Camisa, B., De Girardi, F., Biondi, M., Giglio, F., Ciceri, F., Bonini, C., Bondanza, A., & Casucci, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01217 · Cited by 134

Hydroxycholesterol substitution in ionizable lipid nanoparticles for mRNA delivery to T cells

Patel, S. K., Billingsley, M. M., Frazee, C. P., Han, X., Swingle, K. L., Qin, J., Alameh, M., Wang, K., Weissman, D., & Mitchell, M. J. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.05.020 · Cited by 142

In the Eye of the Storm: Immune‐mediated Toxicities Associated With CAR‐T Cell Therapy

Borrega, J. G., Gödel, P., Rueger, M. A., Onur, O. A., Shimabukuro‐Vornhagen, A., Kochanek, M., & Böll, B. (2019) · HemaSphere · doi:10.1097/hs9.0000000000000191 · Cited by 140

Automated design of thousands of nonrepetitive parts for engineering stable genetic systems

Hossain, A., Lopez, E., Halper, S. M., Cetnar, D. P., Reis, A. C., Strickland, D., Klavins, E., & Salis, H. M. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0584-2 · Cited by 133

Safety and antitumor activity of GD2-Specific 4SCAR-T cells in patients with glioblastoma

Liu, Z., Zhou, J., Yang, X., Liu, Y., Zou, C., Lv, W., Chen, C., Cheng, K. K. Y., Chen, T., Chang, L., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-022-01711-9 · Cited by 134

CAR-T Cell Therapy for Breast Cancer: From Basic Research to Clinical Application

Yang, Y.-H., Liu, J., Lu, C., & Wei, J. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.70120 · Cited by 135

Engineered extracellular vesicles and their mimetics for cancer immunotherapy

Liu, C., Wang, Y., Li, L., He, D., Chi, J., Li, Q., Wu, Y., Zhao, Y., Zhang, S., Wang, L., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.05.062 · Cited by 134

Cancer Spheroids and Organoids as Novel Tools for Research and Therapy: State of the Art and Challenges to Guide Precision Medicine

Harane, S. E., Zidi, B., Harane, N. E., Krause, K., Matthes, T., & Preynat‐Seauve, O. (2023) · Cells · doi:10.3390/cells12071001 · Cited by 135

Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy

Lei, T., Wang, Y., Zhang, Y., Yang, Y., Cao, J., Huang, J., Chen, J., Chen, H., Zhang, J., wang, L., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02444-y · Cited by 155

The UniCAR system: A modular CAR T cell approach to improve the safety of CAR T cells

Bachmann, M. P. (2019) · Immunology Letters · doi:10.1016/j.imlet.2019.05.003 · Cited by 129

Future Trends in Synthetic Biology—A Report

Karoui, M. E., Flight, M. H., & Fletcher, L. (2019) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2019.00175 · Cited by 130

Cytokine Release Syndrome Associated with T-Cell-Based Therapies for Hematological Malignancies: Pathophysiology, Clinical Presentation, and Treatment

Cosenza, M., Sacchi, S., & Pozzi, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147652 · Cited by 134

Extracellular‐Vesicle‐Based Drug Delivery Systems for Enhanced Antitumor Therapies through Modulating the Cancer‐Immunity Cycle

Yong, T., Wei, Z., Gan, L., & Yang, X. (2022) · Advanced Materials · doi:10.1002/adma.202201054 · Cited by 129

mRNA nanomedicine: Design and recent applications

Kubiatowicz, L. J., Mohapatra, A., Krishnan, N., Fang, R. H., & Zhang, L. (2022) · Exploration · doi:10.1002/exp.20210217 · Cited by 131

Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer

Lv, J., Zhao, R., Wu, D., Zheng, D., Wu, Z., Shi, J., Wei, X., Wu, Q., Long, Y., Lin, S., et al. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0704-y · Cited by 130

Engineering interferons and interleukins for cancer immunotherapy

Holder, P. G., Lim, S. A., Huang, C., Sharma, P. A., Dagdas, Y. S., Bulutoglu, B., & Sockolosky, J. T. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114112 · Cited by 130

The Next Generation of Immunotherapy for Cancer: Small Molecules Could Make Big Waves

Kerr, W. G., & Chisholm, J. D. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1800991 · Cited by 131

Efficacy and Safety of CD28- or 4-1BB-Based CD19 CAR-T Cells in B Cell Acute Lymphoblastic Leukemia

Zhao, X., Yang, J., Zhang, X., Lu, X., Xiong, M., Zhang, J., Zhou, X., Qi, F., He, T., Ding, Y., et al. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.06.016 · Cited by 132

The link between kidney disease and cancer: complications and treatment

Małyszko, J., Tesařová, P., Capasso, G., & Capasso, A. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30540-7 · Cited by 134

Lost in Translation: Traversing the Complex Path from Genomics to Therapeutics in Autism Spectrum Disorder

Sestan, N., & State, M. W. (2018) · Neuron · doi:10.1016/j.neuron.2018.10.015 · Cited by 127

Recent updates on cancer immunotherapy

Liu, M., & Guo, F. (2018) · Precision Clinical Medicine · doi:10.1093/pcmedi/pby011 · Cited by 133

Compensatory CSF2-driven macrophage activation promotes adaptive resistance to CSF1R inhibition in breast-to-brain metastasis

Klemm, F., Möckl, A., Salamero‐Boix, A., Alekseeva, T., Schäffer, A., Schulz, M., Niesel, K., Maas, R. R., Groth, M., Elie, B. T., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00254-0 · Cited by 127

PD-L1 blockade restores CAR T cell activity through IFN-γ-regulation of CD163+ M2 macrophages

Yamaguchi, Y., Gibson, J., Ou, K., Lopez, L. S., Ng, R. H., Leggett, N. A., Jönsson, V. D., Zarif, J. C., Lee, P. P., Wang, X., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004400 · Cited by 136

The Multifaceted Output of c-Jun Biological Activity: Focus at the Junction of CD8 T Cell Activation and Exhaustion

Papavassiliou, A. G., & Musti, A. M. (2020) · Cells · doi:10.3390/cells9112470 · Cited by 124

Pancreatic cancer in 2021: What you need to know to win

Tonini, V., & Zanni, M. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i35.5851 · Cited by 133

Inhibition of MICA and MICB Shedding Elicits NK-Cell–Mediated Immunity against Tumors Resistant to Cytotoxic T Cells

de Andrade, L. F., Kumar, S., Luoma, A., Ito, Y., da Silva, P. H. A., Pan, D., Pyrdol, J. W., Yoon, C. H., & Wucherpfennig, K. W. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0483 · Cited by 131

The WNT/ROR Pathway in Cancer: From Signaling to Therapeutic Intervention

Menck, K., Heinrichs, S., Baden, C., & Bleckmann, A. (2021) · Cells · doi:10.3390/cells10010142 · Cited by 131

Vascular Microenvironment, Tumor Immunity and Immunotherapy

Lamplugh, Z. L., & Fan, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.811485 · Cited by 131

Immunosuppressive reprogramming of neutrophils by lung mesenchymal cells promotes breast cancer metastasis

Gong, Z., Li, Q., Shi, J., Li, P., Hua, L., Shultz, L. D., & Ren, G. (2023) · Science Immunology · doi:10.1126/sciimmunol.add5204 · Cited by 130

Cancer Resistance to Immunotherapy: Comprehensive Insights with Future Perspectives

Said, S. S., & Ibrahim, W. N. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041143 · Cited by 134

Comprehensive Immune Monitoring of Clinical Trials to Advance Human Immunotherapy

Hartmann, F. J., Babdor, J., Gherardini, P. F., Amir, E.-A. D., Jones, K., Sahaf, B., Marquez, D. M., Krutzik, P., O’Donnell, E., Sigal, N., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.06.049 · Cited by 124

Recent advances in the design and applications of near-infrared II responsive small molecule phototherapeutic agents

Ma, D., Bian, H., Gu, M., Wang, L., Chen, X., & Peng, X. (2024) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2024.215677 · Cited by 124

Innate Immune Signaling Organelles Display Natural and Programmable Signaling Flexibility

Tan, Y., & Kagan, J. C. (2019) · Cell · doi:10.1016/j.cell.2019.01.039 · Cited by 131

Advances in NK cell production

Fang, F., Xie, S., Chen, M., Li, Y., Yue, J., Ma, J., Shu, X., He, Y., Xiao, W., & Tian, Z. (2022) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00808-3 · Cited by 132

Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?

Hilmi, M., Bartholin, L., & Neuzillet, C. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i20.2137 · Cited by 126

Platelet-Mediated Protection of Cancer Cells From Immune Surveillance – Possible Implications for Cancer Immunotherapy

Schmied, L., Höglund, P., & Meinke, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.640578 · Cited by 121

Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers

Golde, T. E. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01201-2 · Cited by 119

Multiplexed activation of endogenous genes by CRISPRa elicits potent antitumor immunity

Wang, G., Chow, R. D.-W., Bai, Z., Zhu, L., Errami, Y., Dai, X., Dong, M. B., Ye, L., Zhang, X., Renauer, P. A., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0500-4 · Cited by 120

Microfluidic and Nanofluidic Intracellular Delivery

Hur, J., & Chung, A. J. (2021) · Advanced Science · doi:10.1002/advs.202004595 · Cited by 123

Engineered triple inhibitory receptor resistance improves anti-tumor CAR-T cell performance via CD56

Zou, F., Lu, L., Liu, J., Xia, B., Zhang, W., Hu, Q., Liu, W., Zhang, Y., Lin, Y., Jing, S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11893-4 · Cited by 120

Cancer biomarkers for targeted therapy

Liu, D. (2019) · Biomarker Research · doi:10.1186/s40364-019-0178-7 · Cited by 118

Precision medicine: In vivo CAR therapy as a showcase for receptor-targeted vector platforms

Michels, A., Ho, N., & Buchholz, C. J. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.05.018 · Cited by 131

Lipid nanoparticles outperform electroporation in mRNA-based CAR T cell engineering

Kitte, R., Rabel, M., Geczy, R., Park, S., Fricke, S., Koehl, U., & Tretbar, S. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.101139 · Cited by 124

Hepatocellular carcinoma: Mechanisms of progression and immunotherapy

Jiang, Y., Han, Q., & Zhang, J. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i25.3151 · Cited by 122

Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning

Haber, L., Olson, K., Kelly, M. P., Crawford, A., DiLillo, D. J., Tavaré, R., Ullman, E., Mao, S., Canova, L., Sineshchekova, O., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-93842-0 · Cited by 120

Advances and applications of nanoparticles in cancer therapy

Huang, X., He, T., Liang, X., Xiang, Z., Liu, C., Zhou, S., Luo, R., Bai, L., Kou, X., Li, X., et al. (2024) · MedComm – Oncology · doi:10.1002/mog2.67 · Cited by 130

Cancer-associated fibroblasts: key determinants of tumor immunity and immunotherapy

Barrett, R., & Puré, E. (2020) · Current Opinion in Immunology · doi:10.1016/j.coi.2020.03.004 · Cited by 119

Targeting phosphatidylserine for Cancer therapy: prospects and challenges

Chang, W., Fa, H., Xiao, D., & Wang, J. (2020) · Theranostics · doi:10.7150/thno.45125 · Cited by 122

Bacterial therapies at the interface of synthetic biology and nanomedicine

Hahn, J., Ding, S., Im, J., Harimoto, T., Leong, K. W., & Danino, T. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-023-00119-4 · Cited by 125

The paradoxical role of cytokines and chemokines at the tumor microenvironment: a comprehensive review

Abdul‐Rahman, T., Ghosh, S., Badar, S. M., Nazir, A., Bamigbade, G. B., Aji, N., Roy, P., kachani, H., Garg, N. K., Lawal, L., et al. (2024) · European journal of medical research · doi:10.1186/s40001-024-01711-z · Cited by 131

Chimeric antigen receptor macrophages (CAR-M) sensitize HER2+ solid tumors to PD1 blockade in pre-clinical models

Pierini, S., Gabbasov, R. T., Oliveira-Nunes, M. C., Qureshi, R., Worth, A. M., Huang, S., Nagar, K. K., Griffin, C., Lian, L., Yashiro–Ohtani, Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-55770-1 · Cited by 123

Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy

Sterner, R. C., & Sterner, R. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.879608 · Cited by 121

Chimeric antigen receptor (CAR) T cells targeting a pathogenic MHC class II:peptide complex modulate the progression of autoimmune diabetes

Zhang, L., Sosinowski, T., Cox, A. R., Cepeda, J. R., Sekhar, N. S., Hartig, S. M., Miao, D., Yu, L., Pietropaolo, M., & Davidson, H. W. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.08.004 · Cited by 112

Trial Watch: Adoptive cell transfer for oncological indications

Aranda, F., Buqué, A., Bloy, N., Castoldi, F., Eggermont, A. M. M., Cremer, I., Fridman, W. H., Fucikova, J. P., Galon, J., Špíšek, R., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1046673 · Cited by 33

Chimeric Antigen Receptor– and TCR-Modified T Cells Enter Main Street and Wall Street

Barrett, D. M., Grupp, S. A., & June, C. H. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500751 · Cited by 182

Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer

Lundh, S. M., Jung, I.-Y., Dimitri, A. J., Vora, A., Melenhorst, J. J., Jadlowsky, J. K., & Fraietta, J. A. (2020) · Clinical and Experimental Medicine · doi:10.1007/s10238-020-00628-1 · Cited by 10

Improving cell reinfusion to enhance the efficacy of chimeric antigen receptor T-cell therapy and alleviate complications

Han, Z., Ma, X., & Ma, G. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e28098 · Cited by 3

Abstract KN01: Updates on engineered T cells as cancer therapies

June, C. H. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-15-kn01